Aster DM Healthcare Q4 Results Review - Margin, Bed Expansion To Drive Growth: Prabhudas Lilladher
Capex requirement of Rs 10-12 billion for expansion plan of 1,700 beds in the next three years in India.31-05-2024
31-05-2024
Aster DM Healthcare Results Earnings Call for Q4FY24
Conference Call with Aster DM Healthcare Management and Analysts on Q4FY24 Performance and Outlook. Listen to the full earnings transcript. Management in attendance: Alisha Moopen and senior management team30-05-2024
Aster DM Healthcare reports consolidated net loss of 2.17 crore in Q4 FY24
In FY24, the consolidated profit declined by 55.5 per cent y-o-y to 211.56 crore as compared to 475.49 crore in FY2329-05-2024
Aster DM Healthcare Ltd - 540975 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
With reference to the captioned subject please be informed that the Earnings Call of the Company for the quarter and year ended March 31, 2024, was held today, May 29, 2024 and the Video/Audio Recording with respect to Earnings Call is available on the website of the Company at https://www.asterdmhealthcare.com/investors/financial-information/audio-video-recordings-earnings-quarterly-calls . Kindly take the above said information on record as per the requirement of SEBI Listing Regulations.29-05-2024
Q4FY24 Quarterly & FY24 Annual Result Announced for Aster DM Healthcare Ltd.
Healtcare Services company Aster DM Healthcare announced Q4FY24 & FY24 results: Revenue: Revenue grew 24% YoY to Rs 3,699 crore in FY24 Vs. Rs 2,983 crore in FY23. Revenue grew 22% YoY to Rs 978 crore in Q4FY24 Vs. Rs 804 crore in Q4FY23. EBITDA: Operating EBITDA grew 30% YoY to Rs 620 crore in FY24 Vs. Rs 477 crore in FY23. Operating EBITDA grew 24% YoY to Rs 167 crore in Q4FY24 Vs. Rs 135 crore in Q4FY23. Profits: PBT grew by 34% YoY to Rs 281 crore in FY24 Vs. Rs 210 crore In FY23. Adjusted PAT grew by 63% YoY to Rs 240 crore In FY24 Vs. Rs 147 crore In FY23. Reported PAT grew by 28% YoY to Rs 188 crore in FY24 Vs. Rs 147 crore in FY23. Dividend: For financial year 2024, the Board recommended a 20% final dividend of Rs 2.0 /- (face value of Rs 10 each) per equity share. The dividend is subject to the approval of shareholders in the Annual General Meeting (AGM) of the Company Commenting on the update on GCC segregation and performance for Q4 and full year FY24, Azad Moopen, Founder and Chairman, Aster DM Healthcare, said: “I am pleased to announce that we have successfully completed the segregation of our India and GCC businesses, obtaining all necessary regulatory approvals and fulfilling the conditions diligently. I want to express my deepest appreciation to all our stakeholders for their support in ushering in a new era to shape Aster India's future. The segregation has allowed us to tailor our strategies to the distinct growing needs of these geographies and position us to seize the unprecedented growth opportunities in the Indian healthcare market. In FY24, our India business showcased a remarkable 24% YoY revenue growth, surging to Rs 3,699 crores, aided by an increase in bed capacity of 550+ beds and ARPOB growth of 10% in FY24. The Operating EBITDA grew by 30% YoY to Rs.620 crores, supported by the better performance of our mature hospitals delivering 22.4% Operating EBITDA margin in FY24,” Dr. Moopen further added, “I am also pleased to share that we have been conferred with the title of 'Hospital Chain of the Year' at the ET Healthcare Award and Financial Express Healthcare Awards for the year FY23-24. Additionally, Aster Medcity (Kochi) and Aster CMI (Bengaluru) are ranked among top multispecialty hospitals across India by Times of India, Outlook, Newsweek and The Week. As we progress on our journey, we are on track to add ~1700 beds to reach to 6,500+ beds by FY27 through a prudent mix of brownfield and greenfield projects which will result in our Aster Medcity and Aster CMI hospitals expanding to 950+ beds and 850+ beds respectively. This move demonstrates our unwavering dedication to reinforcing our prominent position among India's top healthcare providers. We are happy to have closed the year with Aster India leading the growth metrics across the healthcare peers in the country. We are committed to continuing on this trajectory as the company embarks on a new chapter of future growth.” Result PDF29-05-2024
Aster DM Healthcare Ltd - 540975 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Pursuant to Regulation 24A of SEBI (Listing Obligation and Disclosure Requirements) (Amendment) Regulations, 2018 read with SEBI circular no: CIR/CFD/CMD1/27/2019 dated February 8, 2019, please find enclosed the Annual Secretarial Compliance Report of the Company for the financial year ended 31st March, 2024. We request you to kindly take this on record.29-05-2024
Aster DM Healthcare Ltd - 540975 - Announcement under Regulation 30 (LODR)-Investor Presentation
With reference to the above captioned subject, Please find enclosed the Investor Presentation on the Company''s performance for the quarter and year 31st March, 2024. Kindly take the above said information on record.28-05-2024
Aster DM Healthcare Ltd - 540975 - Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation, 2015 (''LODR Regulations'')
With reference to the above captioned subject, Please be informed that the Company wishes to update that following the receipt of an anonymous complaint pertaining to certain employees of the Company and its subsidiaries, the Company undertook a review with the assistance of a third party and identified certain instances requiring disclosure under the SEBI (LODR) Regulations. Kindly take the above said information on record.28-05-2024
Aster DM Healthcare Ltd - 540975 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the above captioned subject, please find enclosed press release in relation to the audited financial results of the Company for the quarter and year ended 31st March, 2024. We request you to kindly take the above said information on record.28-05-2024
Aster DM Healthcare Ltd - 540975 - Record Date For 16Th Annual General Meeting Of The Company And Payment Of Final Dividend
Please be informed that the Record date for determining the eligibility of shareholders to vote on the resolutions proposed at the 16th Annual General Meeting of the Company and for the payment of the Final Dividend has been fixed as August 22, 2024. We request you to kindly take the above said information on record.28-05-2024